HOOKIPA Pharma To Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 19, 2020
March 10 2020 - 8:15AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that it will release fourth quarter and full year 2019
financial results before the market opens on Thursday, March 19,
2020. Following the release, the Company will host a live
conference call and webcast at 8:00 a.m. EDT to discuss its
financial results and corporate update.
To access the live conference call, please dial
+1-631-510-7495 (from the US) or +44-207-1 92-8000 (international)
and refer to conference ID 1769733. A live audio webcast of the
event will also be available within the Investors & Media
section of HOOKIPA’s website at
https://ir.hookipapharma.com/events. An archived replay will be
accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration to augment and refresh immune
responses. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in
vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
Cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living Cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B
infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The TheraT®
based lead oncology product candidates, HB-201 and HB-202, are in
development for the treatment of Human Papilloma Virus16-positive
cancers. The Phase 1/2 clinical trial for HB-201 was initiated in
December 2019. The HB-202 IND submission is intended for the first
half of 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
For further information, please contact:
MediaNina Waibel Senior Director -
Communications Nina.Waibel@HookipaPharma.com
InvestorsMatt BeckExecutive Director - Investor
RelationsMatthew.Beck@HookipaPharma.com
Media enquiries Ashley Tapp Instinctif Partners
Hookipa@Instinctif.com +44 (0)20 7457 2020
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024